AstraZeneca: European Commission Approves Breast Cancer Treatment

By Rory Gallivan Features Dow Jones Newswires

AstraZeneca PLC (AZN.LN) Wednesday said the European Commission approved its breast cancer treatment Faslodex for post-menopausal women after a Phase III trial showed it reduces the risk of disease progression by 20% compared with anastrozole, the current standard treatment.

Continue Reading Below

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

July 26, 2017 12:15 ET (16:15 GMT)